Rectify to Present RTY-406 Data at Liver Meeting
The oral dual-acting ABCB4/BSEP modulator will be featured in an Industry Research Showcase in Denver, Colorado.
Updated on Nov. 5, 2026 in Healthcare
Rectify Pharmaceuticals will present preclinical data on RTY-406, an investigational oral, once-daily therapy, during the Industry Research Showcase at the AASLD Liver Meeting on November 7, 2026. The presentation covers a mouse model and non-human primate study examining the drug's effects on disease-relevant markers in primary sclerosing cholangitis (PSC).
Why it matters
RTY-406 is being evaluated in clinical trials for primary biliary cholangitis, cholestatic patients with ABCB4 mutations, and PSC, a condition with limited treatment options. The preclinical data aim to support its potential as a disease-modifying therapy.
The preclinical evidence comes from a mouse model and non-human primate study, with dose-dependent effects measured across ductular reaction, inflammation, and fibrosis endpoints. Human data from cholestatic patients in Phase 1 trials are anticipated in 2027, and no human efficacy figures have yet been disclosed.
The players
Rectify Pharmaceuticals
Rectify Pharmaceuticals is a biopharmaceutical company developing RTY-406 as a dual-acting ABCB4/BSEP modulator for liver diseases.
AASLD Liver Meeting
The AASLD Liver Meeting is the annual scientific conference of the American Association for the Study of Liver Diseases, where hepatology research is presented.
The details
RTY-406 increases the function of both the ABCB4 and BSEP protein transporters to restore bile composition and flow, which the company says demonstrates anti-gallstone and anti-cholestasis activity. The presentation, titled 'Targeting bile composition in PSC,' was made during the Industry Research Showcase at The Liver Meeting in Denver, Colorado.
Timeline
November 7, 2026: Rectify presents RTY-406 preclinical data at the AASLD Liver Meeting in Denver, Colorado.
2027: Anticipated data from cholestatic patients in Phase 1 clinical trials.
Market Landscape
Presenting at the AASLD Liver Meeting's Industry Research Showcase places RTY-406 within the venue where companies pursuing cholestatic liver disease therapies share preclinical evidence. The data bear on primary sclerosing cholangitis, a disease area that currently lacks approved disease-modifying treatments.
For patients with primary sclerosing cholangitis or other cholestatic liver conditions, RTY-406 remains investigational and is not yet available. Any eventual access would depend on clinical trial results and regulatory review, which have not yet occurred.
The takeaway
RTY-406 is still in early testing, so its potential benefit to PSC patients rests on clinical data expected in 2027. Readers should watch for human trial results before drawing conclusions about efficacy.
What happens next
Patient data from cholestatic patients in Phase 1 clinical trials are anticipated in 2027.
Further reading
Explore more Healthcare business news for context on drug development and clinical research.
Source note: This article includes information reported by The Manila times.
